HUE059159T2 - T-sejt-receptorok - Google Patents

T-sejt-receptorok

Info

Publication number
HUE059159T2
HUE059159T2 HUE17717845A HUE17717845A HUE059159T2 HU E059159 T2 HUE059159 T2 HU E059159T2 HU E17717845 A HUE17717845 A HU E17717845A HU E17717845 A HUE17717845 A HU E17717845A HU E059159 T2 HUE059159 T2 HU E059159T2
Authority
HU
Hungary
Prior art keywords
cell receptors
receptors
cell
Prior art date
Application number
HUE17717845A
Other languages
English (en)
Inventor
Conor Hayes
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of HUE059159T2 publication Critical patent/HUE059159T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
HUE17717845A 2016-04-08 2017-04-07 T-sejt-receptorok HUE059159T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201606009 2016-04-08

Publications (1)

Publication Number Publication Date
HUE059159T2 true HUE059159T2 (hu) 2022-10-28

Family

ID=58548761

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17717845A HUE059159T2 (hu) 2016-04-08 2017-04-07 T-sejt-receptorok

Country Status (29)

Country Link
US (2) US11505590B2 (hu)
EP (2) EP3440105B1 (hu)
JP (1) JP7254519B2 (hu)
KR (1) KR102473964B1 (hu)
CN (1) CN109563148B (hu)
AU (2) AU2017246693B2 (hu)
BR (1) BR112018070741A2 (hu)
CA (1) CA3020214A1 (hu)
CL (1) CL2018002859A1 (hu)
CO (1) CO2018011972A2 (hu)
CR (1) CR20180531A (hu)
DK (1) DK3440105T3 (hu)
ES (1) ES2914648T3 (hu)
HR (1) HRP20220865T1 (hu)
HU (1) HUE059159T2 (hu)
IL (2) IL308831A (hu)
LT (1) LT3440105T (hu)
MA (1) MA44608B1 (hu)
MD (1) MD3440105T2 (hu)
MX (1) MX2018012318A (hu)
MY (1) MY198621A (hu)
PE (1) PE20190335A1 (hu)
PH (1) PH12018502158A1 (hu)
PL (1) PL3440105T3 (hu)
PT (1) PT3440105T (hu)
RS (1) RS63371B1 (hu)
SG (1) SG11201808797XA (hu)
SI (1) SI3440105T1 (hu)
WO (1) WO2017175006A1 (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3440104B2 (en) * 2016-04-08 2023-06-14 Adaptimmune Limited T cell receptors
SG11201808709VA (en) * 2016-04-08 2018-11-29 Adaptimmune Ltd T cell receptors
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
WO2019133443A1 (en) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Modified t cell receptors
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
CA3094468A1 (en) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
MX2021008578A (es) 2019-01-17 2021-10-22 Immunocore Ltd Formulaciones.
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
EP3986938A4 (en) * 2019-06-18 2023-06-28 Regeneron Pharmaceuticals, Inc. Mage-a4 t cell receptors and methods of use thereof
BR112021026376A2 (pt) 2019-06-25 2022-05-10 Gilead Sciences Inc Proteínas de fusão flt3l-fc e métodos de uso
JP7296467B2 (ja) * 2019-12-18 2023-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｌａ－ａ２／ｍａｇｅ－ａ４に結合する抗体
AU2021219668A1 (en) 2020-02-14 2022-08-25 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
JP2023527293A (ja) * 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022190009A1 (en) 2021-03-09 2022-09-15 Cdr-Life Ag Mage-a4 peptide-mhc antigen binding proteins
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
TW202328212A (zh) 2021-12-01 2023-07-16 英商英美偌科有限公司 Ｍａｇｅ—ａ４陽性癌症之治療
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
CN117106060A (zh) * 2022-05-17 2023-11-24 香雪生命科学技术（广东）有限公司 一种识别mage的高亲和力t细胞受体及其应用
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024038193A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038198A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
US20240092859A1 (en) 2022-08-18 2024-03-21 Immunocore Ltd T cell receptors and fusion proteins thereof
WO2024056758A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977886A4 (en) 1997-03-07 2002-10-23 Sunol Molecular Corp FUSION PROTEINS, WHICH CONTAIN A BACTERIOPHAGE ENVELOPE PROTEIN AND A SINGLE CHAIN T-CELL RECEPTOR
AU742650B2 (en) 1997-10-02 2002-01-10 Altor Bioscience Corporation Soluble single-chain T-cell receptor proteins
WO2000020445A2 (en) * 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
MX340559B (es) 1999-12-06 2016-07-14 Board Of Trustees Of The Univ Of Illinois Proteinas de tcr de alta afinidad y metodos.
EP1259601A2 (en) 2000-02-22 2002-11-27 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
PL208712B1 (pl) 2001-08-31 2011-05-31 Avidex Ltd Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
JP4436319B2 (ja) 2002-10-09 2010-03-24 メディジーン リミテッド 単鎖組換えｔ細胞レセプター
WO2004044004A2 (en) 2002-11-09 2004-05-27 Avidex Limited T cell receptor display
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
SI2275441T1 (sl) 2005-04-01 2016-11-30 Immunocore Ltd. T celični receptorji z visoko afiniteto HIV
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
WO2013039889A1 (en) 2011-09-15 2013-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
CA2850961A1 (en) * 2011-10-14 2013-04-18 Teva Pharmaceuticals Australia Pty Ltd. Antibodies to cd1d
KR102321909B1 (ko) 2011-10-28 2021-11-05 리제너론 파아마슈티컬스, 인크. 유전자 변형된 ｔ 세포 수용체 마우스
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
CN105377886B (zh) * 2013-01-29 2020-07-28 ***-德布鲁克-分子医学中心（Mdc）柏林-布赫 识别mage-a1的高亲和力结合分子
ES2746240T3 (es) 2013-03-13 2020-03-05 Health Research Inc Composiciones y procedimientos para la utilización de receptores de células T recombinantes para el reconocimiento directo de un antígeno tumoral
WO2016007570A2 (en) * 2014-07-09 2016-01-14 The Regents Of The University Of California Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
JP6712261B2 (ja) 2014-08-04 2020-06-24 フレッド ハッチンソン キャンサー リサーチ センター Ｗｔ−１に特異的なｔ細胞免疫治療
KR102528825B1 (ko) 2015-04-13 2023-05-08 화이자 인코포레이티드 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
TWI826891B (zh) 2016-03-16 2023-12-21 德商英麥提克生物技術股份有限公司 轉染 t 細胞和 t 細胞受體用於癌症免疫治療
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso

Also Published As

Publication number Publication date
ES2914648T3 (es) 2022-06-15
RU2018135248A3 (hu) 2020-09-23
CN109563148A (zh) 2019-04-02
KR102473964B1 (ko) 2022-12-06
IL262144B1 (en) 2023-12-01
BR112018070741A2 (pt) 2019-02-12
IL262144A (en) 2018-11-29
SI3440105T1 (sl) 2022-07-29
CL2018002859A1 (es) 2019-04-26
CR20180531A (es) 2019-06-13
US11505590B2 (en) 2022-11-22
US20230322895A1 (en) 2023-10-12
MY198621A (en) 2023-09-11
KR20180132844A (ko) 2018-12-12
AU2017246693A1 (en) 2018-11-22
AU2017246693B2 (en) 2022-07-21
CA3020214A1 (en) 2017-10-12
IL262144B2 (en) 2024-04-01
PE20190335A1 (es) 2019-03-07
EP3440105A1 (en) 2019-02-13
EP3440105B1 (en) 2022-04-27
EP4023668A1 (en) 2022-07-06
PT3440105T (pt) 2022-05-31
DK3440105T3 (da) 2022-06-13
MD3440105T2 (ro) 2022-09-30
CO2018011972A2 (es) 2019-02-08
AU2022256131A1 (en) 2022-11-24
HRP20220865T1 (hr) 2022-10-14
RU2018135248A (ru) 2020-05-12
JP7254519B2 (ja) 2023-04-10
IL308831A (en) 2024-01-01
SG11201808797XA (en) 2018-11-29
PH12018502158A1 (en) 2019-07-15
WO2017175006A1 (en) 2017-10-12
MX2018012318A (es) 2019-07-04
CN109563148B (zh) 2022-10-14
RS63371B1 (sr) 2022-08-31
MA44608B1 (fr) 2022-06-30
US20190092834A1 (en) 2019-03-28
PL3440105T3 (pl) 2022-08-29
LT3440105T (lt) 2022-05-25
MA44608A (fr) 2019-02-13
JP2019516357A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
IL262144A (en) t cell receptors
ZA201806866B (en) T cell receptors
ZA201806862B (en) T cell receptors
IL271435A (en) t cell receptors
ZA201806865B (en) T cell receptors
IL264425B1 (en) t cell receptors against kras-g20
IL251524B (en) t cell receptors
GB201522592D0 (en) T cell receptors
RS64952B1 (sr) T ćelijski receptori
GB201518991D0 (en) T cell receptors